Results 51 to 60 of about 62,013 (267)

A Comparison of Intravenous Infliximab Versus Subcutaneous Infliximab on Remission Rates, Safety, Costs, Patient Preferences in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Gastro Hep Advances
Background and Aims: Infliximab, widely used as a mainstay treatment of inflammatory bowel disease (IBD), is traditionally administered intravenously. The subcutaneous (SC) formulation appears to offer a more convenient route of administration. This is a
Alejandro Nieto Dominguez, Abhishek Bhurwal, Hemant Mutneja, Sarah E. Eichinger, Bhanu Pinnam, Daniel Guifarro Rivera, Chun-Wei Pan   +6 more
doaj   +1 more source

Clinical Images: Methotrexate‐induced melanonychia

Arthritis &Rheumatology, EarlyView.
Yoshinori Taniguchi, Hirotaka Yamamoto
wiley   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study

Gut and Liver
Background/Aims: Infliximab treatment failure in patients with inflammatory bowel disease may result from sub-optimal infliximab trough level. An understanding of pharmacokinetics (PKs) is important to maintain an optimal trough level.
Joo Hye Song, Sung Noh Hong, Myeong Gyu Kim, Minjung Kim, Seong Kyung Kim, Eun Ran Kim, Dong Kyung Chang, Young-Ho Kim   +7 more
doaj   +1 more source

The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial

Pediatric Rheumatology Online Journal, 2010
Background We evaluated the effect of infliximab on markers of inflammation in patients with juvenile idiopathic arthritis (JIA). Methods In this randomized, placebo-controlled substudy, 122 patients with JIA received infliximab 3 mg/kg + methotrexate ...
Gerloni Valeria, Fasth Anders, Baildam Eileen, Apaz Maria T, Gattorno Marco, Espada Graciela, Woo Patricia, Cuttica Ruben, Petty Ross, Martini Alberto, Lovell Daniel J, Marini Joseph C, Wagner Carrie, Visvanathan Sudha, Lahdenne Pekka, Quartier Pierre, Saurenmann Rotraud, Travers Suzanne, Mendelsohn Alan, Xu Stephen, Giannini Edward H, Ruperto Nicolino   +21 more
doaj   +1 more source

Clinical Images: Successfully treated mandibular osteomyelitis by tumor necrosis factor inhibitor in SAPHO syndrome

Arthritis &Rheumatology, EarlyView.
Seiya Oba, Tadashi Hosoya, Shinsuke Yasuda, Kota Yokoyama, Hirofumi Tomioka, Hiroyuki Harada   +5 more
wiley   +1 more source

A Mucoadhesive Hydrogel for Precise Resveratrol Delivery in the Management of Inflammatory Bowel Disease

Food Frontiers, EarlyView.
CMTR‐Gel targeting to the inflamed mucosa by electrostatic interactions. ABSTRACT Natural drug‐food homology compounds have vast therapeutic potential, particularly for inflammatory bowel disease (IBD), but their poor water solubility, instability, and limited mucosal availability hinder their clinical translation.
Wenqiu Xu, Xiaojia Lv, Jilun Ye, Ying Li, Hua Yu, Chenyang Li, Haiqiang Wu, Wei Xiong   +7 more
wiley   +1 more source

Does Smoking Reduce Infliximab’s Effectiveness against Crohn’s Disease?

Canadian Journal of Gastroenterology, 2009
Crohn’s disease (CD) is an idiopathic inflammatory bowel disease and has no known cure. CD symptoms are treated using an array of medicines, including biological agents such as infliximab.
Neeraj Narula, Richard N Fedorak
doaj   +1 more source

Effect of infliximab dose increase in rheumatoid arthritis at different trough concentrations: a cohort study in clinical practice conditions

Frontiers in Medicine, 2015
BackgroundEvidence supporting treatment intensification in rheumatoid arthritis is limited and controversial. We explored outcomes of infliximab dose increases and accounted for pre-existing trough levels in patients with active rheumatoid arthritis (RA).
Chamaida ePlasencia, Teresa eJurado, Alejandro eVillalba, Diana ePeitedado, Maria Teresa López Casla, Laura eNuño, María Gema Bonilla, Ana eMartínez-Feito, Emilio eMartín-Mola, Dora ePascual-Salcedo, Alejandro eBalsa   +10 more
doaj   +1 more source

Dosing Biologic Drugs for Patients with Obesity: One Size Does NOT Fit All

Arthritis &Rheumatology, Accepted Article.
Stephen J. Balevic, Daniel Gonzalez, Bernd Meibohm   +2 more
wiley   +1 more source